ipo
Stage
2
Investors
About
Cabaletta Bio discovers and develops targeted cell therapy product candidates to potentially cure patients with autoimmune diseases. Learn about our CAAR T cell products.
Explore Cabaletta Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.